Clinical Trials Logo

Clinical Trial Summary

Collection of already existing data and images for patients < 2 years of age having MultiHance administration for a MRI of the brain or spine. MR Images will be reviewed during a prospectively designed blinded reading of the images.


Clinical Trial Description

n/a


Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02291822
Study type Observational
Source Bracco Diagnostics, Inc
Contact
Status Completed
Phase N/A
Start date November 2014
Completion date December 2015

See also
  Status Clinical Trial Phase
Completed NCT00329589 - A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients Phase 1
Completed NCT03257631 - A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors Phase 2
Terminated NCT02095353 - Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Active, not recruiting NCT01180881 - Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Completed NCT03750188 - Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
Completed NCT03188354 - Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma N/A
Completed NCT03147989 - Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Not yet recruiting NCT05850377 - 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
Terminated NCT01582152 - Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT04525014 - RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors Phase 1
Terminated NCT02692898 - Biomarker Analysis of Central Nervous System Tumors
Not yet recruiting NCT04671368 - Diagnostic Efficiency of Artificial Intelligence for Surgical Neuropathology N/A
Completed NCT00328458 - EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients Phase 1
Recruiting NCT04859543 - Pediatric Prospective Personalized Immune and Target Identification Trial N/A
Terminated NCT04096716 - Mapping Draining Lymph Nodes in CNS Malignancies Phase 1
Completed NCT01931098 - Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Phase 2
Recruiting NCT05386108 - Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer Phase 1/Phase 2